(Reuters) – Gradually increasing the dose of Biogen Inc’s experimental Alzheimer’s disease drug appeared to reduce the risk of brain swelling compared to higher fixed doses, interim 12-month results from a small study released on Thursday showed. “These data appear solid to us, and if anything provide additional confidence in the program and viability of the titration regimen,” Evercore ISI analyst John Scotti said in a research note late on Thursday. In the group of trial patients given titrated dosing, 35 percent experienced a side effect involving a fluid shift in the brain, compared with 55 percent given a high fixed dose, Biogen said.
Read the original:
Further promising data seen with Biogen Alzheimer’s drug: study
